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Abstract
Background: The collection of exhaled breath condensate (EBC) is a suitable and non-invasive
method for evaluation of airway inflammation. Several studies indicate that the composition of the
condensate and the recovery of biomarkers are affected by physical characteristics of the
condensing device and collecting circumstances. Additionally, there is an apparent influence of the
condensing temperature, and often the level of detection of the assay is a limiting factor. The
ECoScreen2 device is a new, partly single-use disposable system designed for studying different lung
compartments.
Methods:  EBC samples were collected from 16 healthy non-smokers by using the two
commercially available devices ECoScreen2 and ECoScreen at a controlled temperature of -20°C.
EBC volume, pH, NOx, LTB4, PGE2, 8-isoprostane and cys-LTs were determined.
Results: EBC collected with ECoScreen2 was less acidic compared to ECoScreen. ECoScreen2
was superior concerning condensate volume and detection of biomarkers, as more samples were
above the detection limit (LTB4 and PGE2) or showed higher concentrations (8-isoprostane).
However, NOx was detected only in EBC sampled by ECoScreen.
Conclusion: ECoScreen2 in combination with mediator specific enzyme immunoassays may be
suitable for measurement of different biomarkers. Using this equipment, patterns of markers can
be assessed that are likely to reflect the complex pathophysiological processes in inflammatory
respiratory disease.
Background
Exhaled breath condensate (EBC) is the liquid phase of
the respiratory air sampled by cooling and is mainly
formed by water vapour, but volatile substances in gas
phase as well as non-volatile compounds, such as proteins
carried in droplets can dissolve in condensed water during
the sampling [1]. Collection of EBC is a non-invasive tool
for assessing pathophysiologic processes in airway dis-
eases [2]. Since EBC contains no cellular components the
evaluation and quantification of airway or lung pathology
is based on detection of biomarkers [3]. Most of them
were already referred to in induced sputum or BAL and
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both airway and alveolar compartments contribute to the
formation of EBC [4].
However, there are still many methodological limitations,
and the interpretation of findings is hampered by the fact
that the most widely used devices differ significantly in
collection efficiency of markers of interest [5]. There
might be an optimal sampling condition for every media-
tor. However, it is obvious that one collection technique
will not be optimal for all compounds of interest using
EBC as matrix. Therefore, when studying different biomar-
kers in one EBC sample, the methodical setting often is
based on a compromise and should be appropriately eval-
uated [6]. This is also true for the analytical assays con-
cerning sensitivity and specificity versus availability, cost,
and technician time required [7].
Nowadays, different devices are commercially available,
including (in alphabetical order) Anacon (Biostec, Valen-
cia, Spain), ECoScreen (Cardinal Health, Hoechberg, Ger-
many), RTube (Respiratory Research, Charlottesville, VA,
USA), and TURBO-DECCS (ItalChill Pharma and Incofar
Srl, Modena, Italy) [8].
Recent studies highlighted that physical characteristics of
the condensing device affect the biomarker recovery in
EBC. Different adhesion capacities may partly account for
the disparity in the results obtained with different devises.
EBC pH-values obtained with the RTube collection device
were more acidic than those provided by ECoScreen [9].
In healthy volunteers, LTB4 could not be detected in any
sample using immunoassays while cysteinyl-LT (cys-LT)
was present in samples gained by ECoScreen, but not
when RTube or Anacon were used as condensers [10]. In
another study Cys-LT could be quantified by using EIA
kits in EBC samples of RTube and ECoScreen [11]. Influ-
ences of the condensation equipment were also demon-
strated for collection of 8-isoprostane and albumin [12]
or oxides of nitrogen (NOx), total protein, mucin and pH
[13]. Recently, reproducibility of hydrogen peroxide, 8-
isoprostane and cytokines in EBC from healthy adult vol-
unteers was demonstrated to be equally variable for differ-
ent condensing devices [14]. In an excellent review,
reference values of most studied biomarkers were pre-
sented referring to collecting device and analytical proce-
dures as well as data on assay reproducibility,
repeatability, variability and biomarker stability in EBC
samples [15].
The composition of the condensate depends amongst
sampling equipments mainly on cooling temperatures.
The impact of the condensing temperature on pH was
demonstrated using RTube at a starting temperature of -20
or -70°C [10]. The cooling conditions differ between the
widely used devices. A warm-up during condensation is
observed using RTube or the Anacon device, while in the
TURBO-DECCS and ECoScreen device the cooling tem-
perature is stable [10,16].
ECoScreen is commercially available, widely used and
prevents salivatory contamination of EBC. However, this
device may have limitations as exhaled breath conden-
sates on a teflon coated surface that is repeatedly used.
Recently, it was reported that NOx measurements might
be confounded by the device and represent (partly) a con-
tamination with NOx originated from the device itself
[13].
ECoScreen2 (FILT, Berlin, Germany) was designed with
the objective to collect fractionated samples of EBC. For
this purpose, the exhaled volume can be collected into
two separate chambers in a breath-controlled way. Differ-
ent valves separate inspiration from expiration and direct
the exhaled volume according to a threshold volume into
the two chambers and a dead space volume may also be
discarded. According to its design, saliva contamination is
highly unlikely and was excluded in extensive testing by
control of the amylase activity and the viscosity.
The aim of the current study was to compare the temper-
ature-controlled ECoScreen2 with ECoScreen. The
biomarkers studied reflect their widespread application in
assessing the pathophysiology of airway diseases. We eval-
uated inflammatory mediators as leukotriene B4 (LTB4),
cysteinyl-LT (cys-LT; LTC4/LTD4/LTE4) and prostaglandin
E2 (PGE2), the lipid peroxidation marker 8-isoprostane (8-
iso-PGF2α) and the NO metabolites nitrate/nitrite (NO3
-/
NO2
-). EBC pH is a result of the relative amount of differ-
ent volatile and non-volatile components such as CO2,
ammonia, inorganic ions, organic acids, and peptides [1].
It was demonstrated to be lowered in various inflamma-
tory lung diseases and correlated with pro-inflammatory
cytokines in the airways. There is general consensus
regarding the utility of EBC pH as a simple integrative
marker of airway inflammation [17]. To our knowledge,
no comparative data have been published to date on EBC
analysis based on these devices and biomarkers.
Methods
Subjects
Sixteen non-smoking healthy volunteers without lung dis-
eases and occupational exposures to irritative airborne
agents were recruited for the assessment of methodologi-
cal factors on sampling of EBC. A self administered ques-
tionnaire concerning the previous and current medical
history was answered by each subject. Subjects with signif-
icant renal, hepatic, cardiovascular disease, or cancer were
excluded. All participants had no history of chronic respi-
ratory disorders and reported no symptoms of an upper
respiratory infection within the previous six weeks. ThereBMC Pulmonary Medicine 2009, 9:48 http://www.biomedcentral.com/1471-2466/9/48
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were no foci of inflammation in the oral cavity. The
demographic and clinical characteristics of the study pop-
ulation are shown in Table 1. All volunteers underwent
assessment of lung function using a MasterLab pro (Soft-
ware version 4.67a, Cardinal Health, Hoechberg, Ger-
many) within 1 day of the measurement of EBC.
According to the American Thoracic Society (ATS) criteria,
forced vital capacity (FVC) and forced expiratory volume
in 1 sec (FEV1) were obtained from three acceptable lung
function tests [18]. Normal lung function was defined as
FEV1 ≥ 80% predicted and an FEV1/FVC ratio ≥ 70%. The
study was approved by the Medical Ethics Committee of
the Ruhr University of Bochum and all participants gave
written informed consent.
Collection of EBC and study design
EBC was collected in each subject between 8 and 12 a.m.
No food or drinks were allowed 2 h prior to EBC collec-
tion. Before sampling the subjects were asked to rinse
their mouths with water, than EBC was collected during
tidal breathing while sitting comfortably. The subjects
used a nose-clip, breathed through a mouthpiece and a
two-way nonrebreathing valve that also prevented saliva
contamination in addition to an integrated saliva trap.
They were instructed to swallow excess of saliva after com-
ing off the mouthpiece. We compared the commercially
available devices ECoScreen (Cardinal Health, Hoech-
berg, Germany) and ECoScreen2 (FILT, Berlin, Germany)
in a randomised sequential order. Those in the first group
used ECoScreen in the first sampling period and
ECoScreen2 in the second, while in the second group the
order was reversed. EBC collections were performed at the
same day with a 30 min interval between both sample col-
lections.
ECoScreen condensated the exhaled breath on a teflon
coated surface and the sample was collected in a polypro-
pylene cap intended for single use. The teflon coated tube
was washed with high-pure water and wiped clean before
each test. Due to its repeated use, the effect of long term
mechanical wear has to be considered and therefore a
brand-new ECoScreen device was used. In contrast the
ECoScreen2 device directly condensated and collected the
EBC in disposable bags on a special polyethylene surface.
The exact composition and primary source of supply of
the polyethylene plastic film are company secret. For com-
parison reasons, breath parameters were defined and con-
trolled in a way that the complete volume was sampled in
only one ECoScreen2 chamber. The ECoScreen2 feature
of exclusion of a volume representing the dead-space was
also not used.
Minute ventilation was measured by an inserted pneumo-
tachograph (EcoVent, Cardinal Health, Hoechberg, Ger-
many) when using ECoScreen or by an integrated
pneumotachograph in case of ECoScreen2. For each time
point, EBC was collected for exactly 10 min and during
the collection period a temperature of -20°C was main-
tained by both condenser devices.
In order to evaluate repeatability, in a preliminary study
eight subjects used either ECoScreen or ECoScreen2 in a
repeated way under the same conditions (pausing 30 min
between the collections of EBC, similar breathing pat-
terns) and the mean within-subject differences of EBC vol-
ume, pH and mediator concentrations in the samples
were determined.
Sample processing
After EBC collection, samples were immediately divided
in aliquots and stored at -70°C. Stability of the biomark-
ers in the frozen samples was demonstrated before [6].
Within 2 months at -70°C the aliquoted samples were
thawed and analysed for biomarkers. All EBC samples
were analysed in a blinded way for the ECoScreen and
ECoScreen2 device. The samples underwent only one sin-
gle freeze-thaw cycle, were analysed in duplicate or tripli-
cate and run together to exclude interassay variation.
Table 1: Characteristics of the study subjects
Category N Median Range
Gender Male 9
Female 7
Age (years) 39 26 - 62
Smoking status Current/Ex-smokers 0
Non-smokers 16
FVC % predicted 16 108.9 93.1 - 147.2
FEV1% predicted 16 102.5 88.1 - 139.8
FEV1/FVC [%] 16 81.7 70.1 - 93.9
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.BMC Pulmonary Medicine 2009, 9:48 http://www.biomedcentral.com/1471-2466/9/48
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Determination of pH
The pH was measured using a pH-meter with a glass-elec-
trode (Mettler Toledo, Giessen, Germany). The range was
0.00 to 14.00 and the accuracy about 0.01 +/- 0.02. The
pH was measured immediately and after gas standardisa-
tion (deaeration) that was performed with argon at 2 bar
for 10 min.
Determination of NOx
The concentration of nitrogen oxides (NO2/NO3; NOx) in
EBC was determined by a spectrophotometric assay based
on the Griess reaction (Cayman Chemical Company, Ann
Arbor, MI, USA), as previously described [19]. The assay
was performed in triplicates of 80 μL EBC together with 10
μL enzyme cofactors and 10 μL nitrate reductase reacted
with 25 μL Griess reagent. The total NO was measured at
540 nm with a microplate reader (Spectramax Molecular
Devices, Sunnyvale, USA) and calculated by using a stand-
ard curve with the Softmax Pro 4.7.1, software. The range
of quantification was 5 μM - 35 μM. Samples with higher
concentrations were diluted.
Determination of LTB4, PGE2, 8-iso PGF2α and cys-LT
The concentrations of all four biomarkers were measured
by specific competitive immunoassays (Assay Designs,
Ann Arbor, USA). The kits use a polyclonal (in the case of
LTB4 and PGE2) or a monoclonal (for cys-LT and 8-iso-
PGF2α) antibody to bind the relevant marker or an alka-
line phosphatase molecule, which has the biomarker cov-
alently attached to it. After incubation and washing, the
generated yellow colour is read with a microplate reader
(Spectramax Molecular Devices, Sunnyvale, USA) at 405
nm. The intensity of the yellow colour is inversely propor-
tional to the concentrations of the biomarker in either
standards or samples. The optical density is used to calcu-
late the concentration of the biomarker by using the Soft-
max Pro 4.7.1 software utilizing a 4-parameter logistic
curve fitting program. In each assay, the lowest standard
was set as the limit of quantification (LOQ) of the assay.
The LOQ of LTB4 was 11.7 pg/mL and the maximum
cross-reactivity was 5.5% for 6-trans-12-epi-LTB4. The
LOQ of PGE2 was 39.1 pg/mL and the maximum cross-
reactivity was 70% for PGE1. The LOQ of 8-iso PGF2α was
6.1 pg/mL and the maximum cross-reactivity was 4.6% for
PGF1α. The LOQ of cys-LT was 78.1 pg/mL and the mon-
oclonal antibody recognized LTD4 with 115.1%, LTC4
with 100% and LTE4 with 62.7%. Maximum cross-reactiv-
ity was 1.6% for LTB4. All values were measured in dupli-
cate. The intra-assay variability's of the biomarkers by
these specific competitive immunoassays were < 15%.
Statistical analysis
Value distribution was assessed using the D'Agostino &
Pearson omnibus normality test. Repeated measurements
were analyzed as recommended by Bland and Altman
[20]. In addition, repeatability was estimated as correla-
tion and as coefficient of variation (CV = standard devia-
tion/mean as percent), which was calculated as mean of
the individual CVs of the repeated measurements.
Comparisons of paired data were performed with paired
t-test or Wilcoxon test, where appropriate. Values below
the LOQ were set 2/3 of LOQ. The data were analysed by
using GraphPad Prism version 5.01 for Windows (Graph-
Pad Software, San Diego, California, USA, http://
www.graphpad.com). A two-sided significance level of
0.05 was chosen for all tests. Data are expressed as median
with interquartile range. Differences were calculated as
recommended by Bland and Altman. Correlations
between parameters measured with the two devices were
calculated with Pearson's test or Spearman rank test,
where appropriate.
There were no evidences of an influence of the order of the
devices concerning EBC volume, EBC pH and the biomar-
ker investigated according to the statistical approach of
Hills and Armitage [21].
Results
Repeatability
The repeated measurements of volume, pH and the medi-
ators in EBC obtained with the same device within 30
minutes showed a different degree of repeatability. The
mean differences of the two sampling periods (bias), coef-
ficient of variation (CV) and correlations (r2, p and the
intraclass correlation coefficient, ICC) are depicted (Tab
2). The mean concentrations of NOx were different in
EBC sampled by ECoScreen in repeated periods and
showed poorly reproducibility. The intraclass correlation
coefficient for NOx was not calculated because NOx levels
were under the LOQ in half of the subjects. Regarding
LTB4, we noticed that in EBC obtained with ECoScreen, all
samples turned out to be detectable but under the LOQ.
The mean concentration was not significantly different in
the repeated sampling (p = 0.92), however, there was no
correlation of the two periods (p = 0.82). In contrast, con-
centrations of LTB4  in EBC samples collected with
ECoScreen2 were in the linear part of the calibration curve
of the competitive immunoassay. In all the samples tested
for Cys-LT, no activity was detected.
EBC volume
After 10 min of tidal breathing, a significantly higher EBC
volume was collected with ECoScreen2 (median 1825 μL;
interquartile range 1500 - 2225 μL) than with ECoScreen
(1425 (1125-1575) μL; p < 0.01). The measurements
obtained with the two devices revealed a mean within-
subject difference of 412 μL (SD 350 μL). All differences
between the sample volumes lay within ± 2 SD (Fig 1A).
Voluntary ventilations assessed by an integrated pneumo-BMC Pulmonary Medicine 2009, 9:48 http://www.biomedcentral.com/1471-2466/9/48
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tachograph (ECoScreen2) or by Eco-Vent (ECoScreen)
were not significantly different (p > 0.05, data not
shown).
Using ECoScreen exhaled breath condensates directly in a
polypropylene cap where it is sampled. Thereby EBC
presents the total sample amount. In case of ECoScreen2,
the condensate has to be recovered and transferred into a
cap before further sample processing is possible. There is
a loss of condensate during the step of EBC harvesting
(data not shown).
EBC pH
Breath condensate collected with ECoScreen2 was less
acidic than the pH of samples collected with ECoScreen
when pH of EBC was measured immediately (7.24 (6.79 -
7.52) vs. 6.65 (6.42 - 6.87); p < 0.0001). We assessed a
mean difference in the pH levels of 0.47 (SD 0.27) (Fig
1B). The pH values obtained after argon deaeration and
storage were significantly higher than pH values immedi-
ately measured for both ECoScreen2 (7.59 (7.28 - 7.73)
vs. 7.24 (6.79 - 7.52); p < 0.0001) and ECoScreen (7.05
(6.72 - 7.28) vs. 6.65 (6.42 - 6.87); p < 0.0001). The mean
pH value was also significantly elevated after argon treat-
ment (0.49, SD 0.25).
There was a correlation between pH values immediately
determined after collection with both devices (r2 = 0.56; p
< 0.05) that was also apparent after argon treatment (r2 =
0.65; p < 0.01). In linear regression models the correlation
between the devices (ECoScreen to ECoScreen2) was
almost identical for the different methodological
approaches of pH measurements, e.g. immediately deter-
mined (y = 0.74x + 2.27) or after argon treatment and
storage (y = 0.79x + 1.97) (Fig 2).
Biomarkers
All patients were able to produce EBC, however some-
times the sample amounts were not sufficient to measure
all biomarkers. Cys-LT could not be detected in any sam-
ple collected either with ECoScreen or ECoScreen2.
The measurements of NOx, LTB4 and PGE2 were signifi-
cantly influenced by the collection device. Concentrations
of NOx in EBC collected with ECoScreen were 4.3 (3.3 -
7.1) μM, but all ECoScreen2 samples were below the LOQ
of the assay. On the other hand, even though in all sam-
ples LTB4 was demonstrated, only LTB4 samples generated
by ECoScreen2 had substantial concentrations (22.8 (8.9
- 36.7) pg/mL). In all ECoScreen samples, LTB4 concentra-
tions were detectable (about 5 pg/mL) but below the
LOQ.
PGE2 was only detectable and above the LOQ (202.7
(55.6 - 356.1) pg/mL) when EBC was collected with
ECoScreen2. 8-iso PGF2α could be detected and quantified
in every sample. Breath condensate collected with
ECoScreen2 yielded significantly higher concentrations of
Table 2: Results of statistical analysis on repeatability
EcoScreen
Volume pH LTB4 NOx 8-iso PGF2α PGE2
bias % 3.5 0.2 +) 48.9 2.1 +)
CV % 7.7 0.9 166.3 21.4
r2 0.479 0.889 n.c. 0.816
p 0.027 < 0.0001 n.c. 0.002
ICC 0.692 0.943 n.c. 0.903
ECoScreen2
Volume pH LTB4 NOx 8-iso PGF2α PGE2
bias % 0.5 0.7 9.0 +) 3.2 11.9
CV % 8.0 1.0 18.6 11.5 34.4
r2 0.618 0.915 0.656 0.626 0.704
p 0.021 0.0002 0.015 0.017 0.018
ICC 0.786 0.957 0.810 0.791 0.839
Repeated measurements of volume, pH and the mediators in EBC obtained with either the ECoScreen or ECoScreen2 device within 30 minutes. 
Values of the mean differences of sampling period 1 and 2 (bias), CVs and correlations. CV, coefficient of variation; ICC, intraclass correlation 
coefficient; n.c., not calculated. +)mediator concentration < LOQ.BMC Pulmonary Medicine 2009, 9:48 http://www.biomedcentral.com/1471-2466/9/48
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8-iso PGF2α than ECoScreen (464.4 (223.0 - 661.1) pg/mL
vs. 81.9 (70.2 - 241.5) pg/mL; p < 0.01). The levels
obtained with the two devices revealed a mean within-
subject difference of 275 pg/mL (SD 246 pg/mL). There
was no correlation between values collected with both
devices (r = 0.27).
The relative amount of biomarkers above the LOQ and
their values obtained by the different collection devices
are shown in (Table 2).
Discussion
EBC is an attractive non-invasive method for assessing air-
way diseases but its clinical use is still hampered by
methodical limitations [5]. There is accumulating evi-
dence that the physical surface properties of the collecting
devices influence the marker measurement [9,12-14,22].
Moreover, for some markers the applied temperature was
identified as a major confounder [10,11].
The objective of this study was to evaluate the new com-
mercially available temperature-controlled ECoScreen2 in
comparison to the commonly used collecting system ECo-
Screen. The ECoScreen2 device was designed for studying
different lung compartments. It enables breath-controlled
collection into two separate chambers reflecting different
depths of the bronchial system (the airways or the alve-
oli).
EBC samples collected by each device were compared on
the same subject in a cross-over trial during two sampling
periods. Subjects were allocated randomly to two different
groups and EBC collection was performed for each device
at -20°C according to general methodological recommen-
dations on the collection and analysis of EBC [5]. No
influence of the order on the measurements could be
identified. In addition, effects from both time and carry
over effects from the previously sampling period were not
detectable when the same device was repeatedly used.
This underlines the concept of EBC as a non-invasive
method and the usefulness of this method for repeated
sampling. In contrast to invasive methods like BAL or spu-
tum induction there is no reasonable mechanism by
which collection of EBC might significantly alters the air-
way lining fluid. Our randomization design was in line
with previous reports addressing comparison of different
collecting devices [9,11-14] or condensation temperatures
in a sequential manner [10,16]. Usually, a short time
interval of 5 to 15 minutes after every collection was cho-
sen [9,16,23] but there were also trials without any break
[10]. We choose a time period of 30 min for the subjects
to relax and to concentrate on a regular calm tidal breath-
ing during the second period. Under this condition the
subjects managed to breath with a quite similar breathing
pattern during repeated sampling of EBC. Confounding
was further reduced by applying both methods ante meri-
diem.
In preliminary studies the repeatability of both devices
was also assessed under similar conditions. Talking about
variability, it is to stress that in the chosen setting the total
variability has to be taken into account. That includes
intra-subject variability, technical factors of collection and
analytical impact. Intra-subject variability was minimized
by performing both sampling periods sequentially. Col-
lecting of EBC was standardised according to a fixed time,
temperature and breathing pattern. Under these condi-
tions, we could demonstrate acceptable coefficients of var-
iation concerning the volume and EBC-pH.
Reproducibility of volume and pH was comparable for
Comparison of sample volume (A) and EBC-pH (B) obtained  with the two devices Figure 1
Comparison of sample volume (A) and EBC-pH (B) 
obtained with the two devices. Difference between the 
values (ECoScreen2 -- ECoScreen) plotted against the mean 
sample volume according to Bland and Altman [20]. The con-
tinuous line represents the mean difference and the dashed 
lines represent the ± SD for the differences.
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both devices and in accordance with recent findings [14].
Hence, we do believe that one major reason for the higher
variability in biomarker levels was due to the analytical
assays that add most variability to the overall variability.
Referring to LTB4, we could demonstrate that concentra-
tions of mediators within the LOQ favour reproducibility.
Therefore choosing a device that enables a detection of
concentrations above the LOQ may lead to an improve-
ment of biomarker reproducibility. Enhanced mediator
concentrations avoid higher standard deviation in immu-
noassays [7]. Reproducibility expressed as coefficient of
variation was in the line with recently published data
[14,23].
We found that collecting EBC at -20°C resulted in a higher
sample volume with ECoScreen2 than with ECoScreen.
Since the duration of collection for both devices was
exactly 10 min and breathing patterns (measured by
pneumotachograph) were similar, the observed differ-
ences should reflect the different condensing materials.
An influence of the surface material on the efficiency of
condensation was reported earlier [13]. Moreover, it is
obvious that an enlarged condensation surface favours
sampling of an increased EBC volume [14]. Therefore, the
higher sampling volume in case of ECoScreen2 might be
at least attributed to its higher condensing surface. The
volume of the primary condensate should be considered
even higher because the condensate is dispersed to the
high surface of the bags and has to be harvested. Conse-
quently, a reversal is obvious between the primary con-
densate amount and the sample that could be used for
further analysis. In case of ECoScreen, the total amount of
the condensate is sampled in a cap enabling immediate
processing without further volume loss.
Published data reveal that EBC pH is correlated with other
marker for airway inflammation. Low EBC pH in several
respiratory diseases pointing towards the important
pathophysiologic role of airway acidic stress [17]. The
determination of pH with a glass-electrode is an estab-
lished accurate method. However, there are different rec-
ommendations concerning the general conditions of EBC
pH measurements (immediate measurement vs. after
deaeration with a CO2-free gas, mostly argon) as it was
shown that EBC pH is influenced by the CO2 level. EBC
pH measurements after deaeration with argon were found
not to be affected by collection temperatures [24]. When
using a different method with determination of pH at a
normalized standard partial pressure, a change of the con-
densing temperature in the same device was shown to
influence the EBC pH, and samples collected at lower
temperature were more acidic [10]. This technique for pH
measurement was recently introduced promising a further
improvement of the reproducibility [25]. In the present
study, pH values were assessed before and after deaera-
tion. Our general focus was the application of EBC analy-
sis in field studies and therefore we chose not to
determine pH at a normalized standard partial pressure as
this procedure needs more equipment and is time-con-
suming. The methods used in this study for pH measure-
ment have been validated and were previously shown to
be robust and reliable [9,13,24]. Normative data were
characterized in 404 healthy subjects [26]. Our findings of
EBC pH values measured immediately after collection or
with deaeration corroborate our previous results and are
in accordance to the published data referring to ECo-
Screen [6,15].
There are only limited data from comparative studies con-
cerning the methodical impact. In a heterogeneous study
population, higher pH values were reported for ECo-
Screen than RTube regarding non-deaerated EBC samples.
With deaeration the difference was smaller and near to
insignificance [9]. In another study there was no differ-
ence between pH assessed after deaeration in EBC samples
from healthy individuals collected with the ECoScreen or
RTube device [11]. Different pH values with a low correla-
tion were reported between non-deaerated samples col-
Correlations between pH values obtained with ECoScreen  (x--axis) and ECoScreen2 (y-axis) Figure 2
Correlations between pH values obtained with ECo-
Screen (x--axis) and ECoScreen2 (y-axis). A: Immediate 
determination; B: determination after argon treatment and -
70°C storage.
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lected by ECoScreen and RTube in healthy subjects [23].
In contrast, in our comparative design we found a good
correlation between pH values in non-deaerated and in
deaerated EBC obtained by ECoScreen or ECoScreen2.
The pH of EBC depends on a mixture of non-volatile and
volatile components, CO2 being the major one. In our
study the correlation between pH obtained with the dif-
ferent devices could be described by an equation that was
similar for samples before and after deaeration. This result
implicates that the differences of EBC pH are determined
by other acids (or bases).
Stability of NO was demonstrated to be influenced by col-
lecting temperature, which may contribute to the
described variation of NOx levels in EBC [27]. Moreover,
elegant control experiments unravel that the device itself
can introduce errors in the measurement of markers and
the NOx sampled by ECoScreen partly represents a con-
tamination with NOx originating from the device itself
[13]. In the EcoScreen, the condensation occurs on the
surface of a re-useable module with modified inner Teflon
coating and the resulting EBC is collected in a disposable
polypropylene cap. Preliminary investigations demon-
strated an effect of the age of the condensing module on
NOx levels. A significant difference could be revealed
when NOx was analysed in samples from the same volun-
teers obtained either with a 20 month-old frequently used
device or a new one, (samples > LOQ 1/16 vs. 8/16, data
not shown). For the current study we use a new ECoScreen
condenser. There was a high variability in the repearted
measurements and no correlation between values
obtained in the first and second period. This further sup-
ports the idea of a contamination with NOx in case of
ECoScreen.
When comparing studies using the same device, the
observed variability of biomarker levels may also be
attributed to an analytical impact, especially of the cur-
rently used immunoassays. At low concentrations, assays
often become nonlinear. Since results are based on inter-
polation, the variability of the assay and thereby the coef-
ficient of variation (CV) increases. Therefore, it is not
surprising that mean CV's are high when biomarker levels
are close to the detection level of the assay. Our compari-
son is based on the LOQ of the assay rather than on the
lower limit of detection [7,28]. We chose different
biomarkers for analysis that reflect different aspects of
inflammation including oxidative stress. Parallel identifi-
cation of different biomarkers is a prerequisite for the
evaluation of special biomarker profiles, which might be
helpful in differential diagnosis or assessment of disease
severity [29].
Immunoreactivity for LTB4 was reported in the majority of
healthy subjects when EBC was sampled with ECoScreen.
Our results are in line with previous investigations report-
ing LTB4 levels in the range of 3.8. to 7.7 pg/mL and close
to the limit of detection [22,30]. Despite the use of a com-
parable methodology some studies demonstrated rather
high LTB4 levels in EBC of healthy subjects [31,32]. In
contrast, no LTB4 could be detected in any sample col-
lected with ECoScreen in a recent study designed to eval-
uate the influence of condensing equipment on
leukotriene concentrations [10]. With the specific enzyme
immunoassay applied in our study the concentrations of
LTB4 were in most samples within the limit of quantifica-
tion using ECoScreen2 and significantly higher compared
to collection with ECoScreen.
Cys-LTs were not in the range of detection in any of our
samples, regardless of the condenser type. Cys-LTs meas-
urements were reported to be measurable in healthy vol-
unteers; however their levels were often near or even
below the LOD of the applied EIA when using ECoScreen
for EBC sampling [22,32]. In two studies higher concen-
trations of Cys-LTs were detected with a commercially
available EIA kit in samples from ECoScreen compared
with RTube [10,11]. Our methodology was different as
another Cys-LT EIA kit was used that was demonstrated in
our laboratory to be effective in fluids like nasal lavage or
sputum. Referring to published data, Cys-LTs concentra-
tions in EBC were reported up to 205 pg/mL [11]. How-
ever, in all the samples tested for Cys-LT, no activity was
detected, suggesting that the sensitivity of our assay (LOQ:
78.1 pg/mL) was not appropriate for the detection of Cys-
LTs in EBC regardless of the type of device used. This is
consistent with previous findings demonstrating Cys-LT
concentrations rather in the range of 15-25 pg/mL [32,33]
or 65 pg/mL [10].
Data on PGE2 levels in EBC are limited. Considering the
anti-inflammatory effects of PGE2 this mediator might be
valuable for evaluating endogenous balance in inflamma-
tory diseases. In most subjects of our study, PGE2 levels
were detectable and in the linear range enabling valid
quantification when using ECoScreen2 for EBC sampling
and EIA for its measurement.
8-iso PGF2α belongs to the group of F2-isoprostanes and
reflects oxidative stress and lipid peroxidation [34]. In
healthy subjects a base-line level of 8-isoprostane could
be verified and an influence of the condensing surface was
demonstrated [12,14]. Compared to these results and a
previous study on healthy smokers using ECoScreen,
which reported a detectability in about half of the subjects
[35], we could detect 8-iso PGF2α in all samples with high
immunoassay activity. We conclude that there is a sub-
stantial impact of the condensing material and
ECoScreen2 was superior resulting in significantly higher
levels of 8-iso PGF2α using the same EIA kit. There was noBMC Pulmonary Medicine 2009, 9:48 http://www.biomedcentral.com/1471-2466/9/48
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correlation for the 8-iso PGF2α concentrations between
both devices.
ECoScreen2 is a temperature-controlled device and in
contrast to ECoScreen it is a single-use disposable con-
densing and collection system. Compared with the
Teflon-coated metal surface of ECoScreen the plastic col-
lecting surface of ECoScreen2 turned out to be more
appropriate for lipid-derived compounds as stated earlier
[8]. This device might be useful for studying different lung
compartments as it allows breath controlled collection of
exhaled breath derived from the airways or the alveoli into
two separate chambers were the respective EBC is sam-
pled. In summary, ECoScreen2 was superior concerning
condensate volume and detection of specific biomarkers.
The number of samples showing values above the LOQ of
LTB4  or PGE2  was higher than in ECoScreen. The
ECoScreen2 condenser was also associated with signifi-
cantly higher concentrations of 8-iso PGF2α.
Variations in biomarker detection in favour of
ECoScreen2 could not simply be attributed to variations
in the dilution as the quantity of condensate was also sig-
nificantly increased. We did not quantify the dilution of
the EBC samples. It was suggested that epithelial lining
fluid concentrations could be calculated from EBC values
by using dilutional indicators like urea, ion measure-
ments or total protein but it is to note that they are also a
source of variability [1,5]. Dilution markers might be
unnecessary as ratios of biomarkers are determined. In
this respect, the EBC pH can be considered as a ratio of
acids and bases and pH was the most reproducible
marker. Moreover, there was a strong correlation between
the values determined by both devices.
Conclusion
Each biomarker has its own chemical and physical charac-
teristics. It was suggested that the most valid and inert
condenser coating should be identified and applied for
the measurement of a specific inflammatory marker. On
the other hand, specific patterns of markers are likely to
reflect more accurately the complex pathophysiological
processes in respiratory disease, since markers of airway
inflammation are differently expressed in different dis-
eases as well as disease severities. The current results dem-
onstrate that ECoScreen2 is a suitable collecting device
that enables detection of different biomarkers that reflect
different aspects of inflammation including oxidative
stress. In addition, the detection of multiple biomarkers is
a condition precedent to calculate ratios that could
strengthen interpretation of changes according to airway
diseases. Further studies are needed to confirm our find-
ings and it would be of particular interest to report con-
centrations of inflammatory markers in fractionated
exhaled breath condensate.
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